{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-22-000072","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.441846+00:00","generated_at":"2026-06-21T05:16:37.998657+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pacira reports Nov 2022 preliminary net product sales of $57.5M; EXPAREL unit volumes up 4% YoY","bullets":["EXPAREL net sales $46.0M (99% of Nov 2021); unit volumes 104% of Nov 2021; selling days flat at 20.","ZILRETTA net sales $10.0M; iovera° net sales $1.5M (unchanged YoY).","Expanded contracting and 340B pricing expected to drive volume growth and be accretive in 2023.","No 2022 revenue or gross margin guidance provided due to COVID-19 and labor shortage uncertainty.","Company continues monthly intra-quarter sales reporting until visibility improves."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-22-000072","json":"https://secwatch.observer/filing/0001396814-22-000072.json","markdown":"https://secwatch.observer/filing/0001396814-22-000072.md","text":"https://secwatch.observer/filing/0001396814-22-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000072/0001396814-22-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000072/pcrx-20221213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:16:37.998657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0f7863fd4f686a7db34e4f2350640aaa182f2c5","claim":"Pacira BioSciences, Inc. reported the month of November 2022 results: revenue $57.5 million.","evidence_excerpt":"Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of $57.5 million for the month of November 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000072/0001396814-22-000072-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the month of November 2022"},{"label":"Revenue","value":"$57.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}